P10 | HIGH ACCURACY OF NEXT-GENERATION FLOW IN PREDICTING MEASURABLE RESIDUAL DISEASE BY NEXT-GENERATION SEQUENCING IN THE 10⁻⁶ RANGE: A PROSPECTIVE COMPARISON WITHIN THE PHASE III EMN24 ISKIA TRIAL

Introduction. Measurable residual disease (MRD) negativity is the strongest single predictor of long-term remission in multiple myeloma (MM). Both next-generation sequencing (NGS; FDA-approved in the US) and next-generation flow (NGF) are standard techniques suggested by the IMWG guidelines for mon...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	M. D'Agostino, M. Van Duin, W. Roeloffzen, M.A. Dimopoulos, L. Rosiñol, M. Van Der Klift, J. Martínez-López, A. Oriol, E. Katodritou, K.L. Wu, P. Rodríguez Otero, R. Hájek, E. Dama, D. Oddolo, G. Gazzera, E.M. Van Leeuwen-Segarceanu, N.W.C.J. Van De Donk, S. De Jonge-Peeters, T.S. Slørdahl, J. Straub, M. Westerman, F. Schjesvold, J. Bladé, H. Einsele, M. Boccadoro, P. Sonneveld, A. Broijl, F. Gay
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Ferrata Storti Foundation 2026-04-01
Reeks:	Haematologica
Online toegang:	https://haematologica.org/article/view/14063
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!